연구성과로 돌아가기

2023 연구자 정보 (57 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Flowers, Mary
(Flowers, M) ⓘ 		Fred Hutchinson Canc Res Ctr, Seattle, WA USA ⓘ
ⓘ 		0000-0003-1631-0911
Flowers, Mary ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Fukushima, Norimasa
(Fukushima, N) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Gane, Ed
(Gane, E) ⓘ 		Univ Auckland, Auckland, New Zealand ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
Gane, Edward J.
(Gane, EJ) ⓘ 		VIR Biotechnol Inc, San Francisco, CA USA
Univ Auckland, Dept Med & Hlth Sci, Auckland, New Zealand ⓘ 		AGN-7071-2022
Gane, Edward ⓘ
ⓘ 		[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
Gankina, Natalya Urievna Gankina Urievna
(Gankina, NUGU) ⓘ 		Krasnojarsk Reg Ctr AIDS prevent, Krasnoyarsk, Russia ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ robert.c.elston@gsk.com; ⓘ
Garcia-Medel, Eric
(Garcia-Medel, E) ⓘ 		Arrowhead Pharmaceut Inc, Pasadena, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
Gasbarrini, Antonio
(Gasbarrini, A) ⓘ 		ⓘ AAB-8487-2019
Gasbarrini, Antonio ⓘ
ⓘ 		[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Gennaro, Nicolo
(Gennaro, N) ⓘ 		ⓘ P-1776-2019
Gennaro, Nicolò ⓘ
ⓘ 		[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Given, Bruce D.
(Given, BD) ⓘ 		Arrowhead Pharmaceut Inc, Pasadena, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ mfyuen@hku.hk; ⓘ
Goh, Myungji
(Goh, M) ⓘ 		Sungkyunkwan Univ, Sch Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Similar recurrence after curative treatment of HBV-related HCC regardless of HBV replication activity ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ ksukorea@yuhs.ac; ⓘ
Gong, Jun
(Gong, J) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Goto, Hiroki
(Goto, H) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Greinix, Hildegard
(Greinix, H) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ dmiklos@stanford.edu; ⓘ
Gunasekaran, Rajendra Kumar
(Gunasekaran, RK) ⓘ 		Kyungpook Natl Univ KNU, Sch Mat Sci & Engn, Daegu 41566, South Korea
Kyungpook Natl Univ, KNU Adv Mat Res Inst, Daegu 41566, South Korea
Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu 41566, South Korea
Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu, South Korea ⓘ 		ISU-5759-2023
Gunasekaran, Rajendra Kumar ⓘ 		0000-0003-1360-0083
Gunasekaran, Rajendra Kumar ⓘ 		[JCR상위 1.7] High-performance self-powered color filter-free blue photodetector based on wide-bandgap halide perovskites
[JCR상위 3.8] Regulating Surface Heterogeneity Maximizes Photovoltage and Operational Stability in Tin-Lead Perovskite Solar Cells
[JCR상위 3.1] High-throughput compositional mapping of triple-cation tin-lead perovskites for high-efficiency solar cells ⓘ 		SCIE ⓘ 1.7 MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING
CHEMISTRY, PHYSICAL;ELECTROCHEMISTRY;ENERGY & FUELS;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY
MATERIALS SCIENCE, MULTIDISCIPLINARY ⓘ 		wook2@knu.ac.kr;
donghoekim@korea.ac.kr;wook2@knu.ac.kr; ⓘ
Gupta, Charu
(Gupta, C) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
페이지 이동: